Lapatinib
From Proteopedia
(Difference between revisions)
| Line 18: | Line 18: | ||
! 115 | ! 115 | ||
! 24.6 | ! 24.6 | ||
| - | ! | + | ! 460 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ! [[Pharmaceutical_Drugs#Bioavailability_.28F.29|Bioavailability]] (%) | ||
| Line 33: | Line 33: | ||
! 9.6 | ! 9.6 | ||
! 83 | ! 83 | ||
| - | ! | + | ! 29 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ! [[Pharmaceutical_Drugs#Area_Under_the_Curve_.28AUC.29|AUC]] (ng/ml/hr) | ||
! 1429 | ! 1429 | ||
! 1921 | ! 1921 | ||
| - | ! | + | ! 11040 |
|- | |- | ||
! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ! [[Pharmaceutical_Drugs#Inhibitory_Concentration_.28IC50.29|IC<sub>50</sub>]] (nM) | ||
| Line 48: | Line 48: | ||
! 100 | ! 100 | ||
! 50 | ! 50 | ||
| - | ! | + | ! 50 |
|- | |- | ||
! Metabolism | ! Metabolism | ||
Revision as of 08:03, 6 December 2010
Pharmacokinetics
| Tyrosine Kinase Inhibitor Pharmacokinetics [1][2] | |||||
|---|---|---|---|---|---|
| Parameter | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Tmax (hr) | 4 | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Cmax (ng/ml) | 115 | 24.6 | 460 | ||
| Bioavailability (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Protein Binding (%) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| T1/2 (hr) | 9.6 | 83 | 29 | ||
| AUC (ng/ml/hr) | 1429 | 1921 | 11040 | ||
| IC50 (nM) | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
| Dosage (mg) | 100 | 50 | 50 | ||
| Metabolism | Lapatinib (Tykerb) | Sunitinib (Sutent) | Sorafenib (Nexavar) | ||
